KIMBERLY CLAY: Open Payments
NPI 1447346887 · MARIETTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,930 in 80 payments from 14 companies in 2025. Trend: 2023 $2,476 · 2024 $1,431 · 2025 $1,930
Food & beverage: $1,871Education: $59
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 17 | $469 |
| AstraZeneca Pharmaceuticals LP | 11 | $230 |
| GlaxoSmithKline, LLC. | 11 | $188 |
| Novartis Pharmaceuticals Corporation | 7 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $175 |
| Regeneron Healthcare Solutions, Inc. | 6 | $139 |
| BioCryst US Sales Co., LLC | 5 | $123 |
| Optinose US, Inc. | 4 | $106 |
| Ionis Pharmaceuticals, Inc. | 4 | $93 |
| CSL Behring | 3 | $73 |
Products named: DUPIXENT, CUVITRU, NUCALA, ORLADEYO, Xhance, TEZSPIRE, Rhapsido, FASENRA.
Industry payments across GA — which companies pay providers there.
